Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PSA-1 and SELECT-PsA-2 trials assessed according to modified PsARC

Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PSA-1 and SELECT-PsA-2 trials assessed according to modified PsARC

Veure altres versions (1)

Dades bibliogràfiques
Autors principals:	Coates, LC, Garrood, T, Gullick, N, Helliwell, P, Kent, T, Marks, J, Tillett, W, Kaur-Papadakis, D, Tahir, H, van Haaren, S, McInnes, I
Format:	Journal article
Idioma:	English
Publicat:	Oxford University Press 2022

Ítems similars

Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC
per: Coates, LC, et al.
Publicat: (2021)

Assessment of the many faces of PsA: single and composite measures in PsA clinical trials
per: McGagh, D, et al.
Publicat: (2020)

Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study
per: Iain B. McInnes, et al.
Publicat: (2022-10-01)

Anti-LL37 Antibodies Are Present in Psoriatic Arthritis (PsA) Patients: New Biomarkers in PsA
per: Loredana Frasca, et al.
Publicat: (2018-09-01)

Treat-to-target in PsA: methods and necessity
per: Dures, E, et al.
Publicat: (2020)

Value of RAPID3 in patients with PsA: results from the TICOPA and LOPAS II databases
per: Coates, L, et al.
Publicat: (2017)

What should be the primary target of ‘treat to target’ in PsA?
per: Coates, L, et al.
Publicat: (2018)

Ethical issues in a TwiCs study in early PsA
per: Coates, L, et al.
Publicat: (2017)

Treat-to-target in PsA: methods and necessity
per: Laura C Coates, et al.
Publicat: (2020-02-01)

Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study
per: Joseph F Merola, et al.
Publicat: (2021-11-01)

Comparative early effectiveness across 14 PsA drugs and 5 classes of PsA treatment: 3-month results from the PRO-SPIRIT study
per: Inmaculada de la Torre, et al.
Publicat: (2024-09-01)

Correction: Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study
Publicat: (2021-12-01)

Usage of C-reactive protein testing in the diagnosis and monitoring of psoriatic arthritis (PsA): results from a real-world survey in the USA and Europe
per: Ogdie, A, et al.
Publicat: (2022)

From PsO to PsA: the role of TRM and Tregs in psoriatic disease, a systematic review of the literature
per: Bárbara Lobão, et al.
Publicat: (2024-02-01)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
per: Helliwell, PS, et al.
Publicat: (2022)

Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA)
per: Mease, P, et al.
Publicat: (2018)

Screening/referral strategies for the early recognition of psoriatic arthritis (PsA) among patients with psoriasis: results of a GRAPPA survey
per: Song, K, et al.
Publicat: (2023)

Sex-specific challenges in patients with psoriatic arthritis (PsA): preliminary results from a systematic literature review (SLR)
per: Coates, LC, et al.
Publicat: (2021)

Treating to target in psoriatic arthritis: assessing real-world outcomes and optimising therapeutic strategy for adults with psoriatic arthritis—study protocol for the MONITOR-PsA study, a trials within cohorts study design
per: Rombach, I, et al.
Publicat: (2021)

Analysis of PsO & PsA Treatment with a Focus on Biologics
per: Vivian Dang, et al.
Publicat: (2021-05-01)

Monotherapy or combination therapy in PsA: current aspects
per: Elpida Skouvaklidou, et al.
Publicat: (2024-09-01)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
per: Atul Deodhar, et al.
Publicat: (2022-07-01)

Identification of PsA phenotypes with machine learning analytics using data from two phase III clinical trials of guselkumab in a bio-naïve population of patients with PsA
per: Julio Ramírez, et al.
Publicat: (2023-03-01)

Spatiotemporal parameters and gait variability in people with psoriatic arthritis (PsA): a cross‐sectional study
per: Roua Walha, et al.
Publicat: (2022-01-01)

Treating to target in psoriatic arthritis: assessing real-world outcomes and optimising therapeutic strategy for adults with psoriatic arthritis—study protocol for the MONITOR-PsA study, a trials within cohorts study design
per: Ines Rombach, et al.
Publicat: (2021-03-01)

Comparing the visual analogue scale (VAS) and the numerical rating scale (NRS) in patient reported outcomes in PsA
per: Ye, W, et al.
Publicat: (2020)

How routine use of a treat to target approach in PsA might impact on clinical decision making
per: Coates, L
Publicat: (2017)

Quality of life improvements in patients with PsA who achieve remission or low disease activity targets: results from two clinical trials of ixekizumab at three years of treatment
per: Coates, LC, et al.
Publicat: (2021)

High prevalence of radiographic erosions in early, untreated PsA: results from the SpARRO cohort
per: Richard J Wakefield, et al.
Publicat: (2024-05-01)

Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project
per: Philip J Mease, et al.
Publicat: (2024-02-01)

Content and face validity and feasibility of 5 candidate instruments for psoriatic arthritis randomized controlled trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting
per: Holland, R, et al.
Publicat: (2018)

Serum Biomarkers of Inflammation and Turnover of Joint Cartilage Can Help Differentiate Psoriatic Arthritis (PsA) Patients from Osteoarthritis (OA) Patients
per: Michał Waszczykowski, et al.
Publicat: (2020-12-01)

Association Between Achievement of Clinical Disease Control and Improvement in Patient‐Reported Outcomes and Quality of Life in Patients With Psoriatic Arthritis in the Phase 3 SELECT‐PsA 1 and 2 Randomized Controlled Trials
per: Arthur Kavanaugh, et al.
Publicat: (2024-11-01)

TOFA-PREDICT study protocol: a stratification trial to determine key immunological factors predicting tofacitinib efficacy and drug-free remission in psoriatic arthritis (PsA)
per: Paco M J Welsing, et al.
Publicat: (2022-10-01)

Sex differences in cytokines and adipokines in obese patients with PsA and controls undergoing a weight loss intervention
per: Ingrid Larsson, et al.
Publicat: (2024-02-01)

Symposium 8 <subtitle>Role of IL-23 Inhibitors in PsA Management — Can It Be Considered Upfront?</subtitle>
per: Peter NASH
Publicat: (2023-11-01)

PSA is dead, long live PSA.
per: Vickers, A, et al.
Publicat: (2012)

Multi-domain effectiveness of guselkumab evaluated via composite indices through 1 year in patients with PsA and inadequate response to TNFi: post hoc analysis of COSMOS
per: Gossec, L, et al.
Publicat: (2024)

Does treat to target or achieving remission improve radiographic outcome in psa?
per: Coates, L, et al.
Publicat: (2016)

Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1
per: Coates, L, et al.
Publicat: (2017)